Bone Biologics Corp
For the period ended Dec 31, 2023. Filed Feb 21, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 21, 2024
BBLG$0.33-0.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| Year Ended December 31, 2023 | Year Ended December 31, 2022 | |
|---|---|---|
| Revenues · $ · - · $ · - | ||
| Operating expenses | ||
| Research and development | 6,907,824 | 1,579,298 |
| General and administrative | 2,520,479 | 2,085,875 |
| Total operating expenses | 9,428,303 | 3,665,173 |
| Loss from operations | (9,428,303) | (3,665,173) |
| Other income (expenses) | ||
| Finance cost related to public offering | - | (731,714) |
| Change in fair value of warrant liability | 892,693 | 2,912,267 |
| Legal settlement, net of insurance | (414,989) | - |
| Interest income | 1,868 | - |
| Total other income (expenses) | 479,572 | 2,180,553 |
| Net loss | $(8,948,731) | $(1,484,620) |
| Weighted average shares outstanding - basic and diluted | 263,137 | 47,658 |
| Loss per share - basic and diluted | $(34.01) | $(31.15) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.